Resources

Browse manuscripts, abstracts, posters, and presentations related to our neurology program.
Journal articles may open on publisher websites and can require subscription access.
Showing 10 resources
Manuscript
Published in Nature
2025

Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease

V. Tabar, H. Sarva, A. M. Lozano, A. Fasano, S. K. Kalia, K. K. H. Yu, C. Brennan, Y. Ma, S. Peng, D. Eidelberg, M. Tomishima, S. Irion, W. Stemple, N. Abid, A. Lampron, L. Studer and C. Henchcliffe
View More Visit Resource
Poster
Presented at MDS
2025

Continued Evaluation of Bemdaneprocel Following a Phase 1 Study for Parkinson’s Disease: Outcomes Through 3 Years

Harini Sarva, MD; Claire Henchcliffe, MD, DPhil; Andres Lozano, MD, PhD; Alfonso Fasano, MD, PhD; Suneil Kalia, MD, PhD, FAANS, FRCSC; Kenny Kwok Hei Yu, MBBS, PhD, FRCS; Cameron Brennan, MD; Melinda Louie-Gao, PhD; Nicole Floro, MS; Nauman Abid, MD; Viviane Tabar, MD
View More Download PDF
Poster
Presented at PSG
2025

exPDite-2: A Phase 3, Randomized, Sham-Controlled, Double-Blind Trial to Evaluate Bemdaneprocel, a Midbrain Dopaminergic Neuron Progenitor Cell Therapy for Parkinson’s Disease

Nauman Abid, MD; Mathews Adera, MD; Melinda Louie-Gao, PhD; Gabriel Belfort, MD, PhD
View More Download PDF
Poster
Presented at MDS
2025

Continued Evaluation of Safety, Motor, and Non-Motor Outcomes in Participants With Parkinson’s Disease Through 3 Years After Bemdaneprocel Administration

Alfonso Fasano, MD, PhD; Harini Sarva, MD; Claire Henchcliffe, MD, DPhil; Andres Lozano, MD, PhD; Suneil Kalia, MD, PhD, FAANS, FRCSC; Kenny Kwok Hei Yu, MBBS, PhD, FRCS; Cameron Brennan, MD; Melinda Louie-Gao, PhD; Nicole Floro, MS; Nauman Abid, MD; Viviane Tabar, MD
View More Download PDF
Poster
Presented at MDS
2024

Motor and Non-Motor Outcomes of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study

Henchcliffe C; Sarva H; Lozano A; Fasano A; Kalia S; Yu K; Brennan C; Stemple W; Abid N; Lampron A; Tabar V
View More Download PDF
Oral Presentation
Presented at MDS
2024

Safety and Tolerability of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study

Sarva H; Henchcliffe C; Lozano A; Fasano A; Kalia S; Yu K; Brennan C; Stemple W; Floro N; Abid N; Lampron A; Tabar V
View More Download PDF
Oral Presentation
Presented at ADPD
2024

Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: Results up to 18 Months From a Phase 1 Study

Henchcliffe C, Sarva H, Lozano A, Fasano A, Kalia S, Yu K, Brennan C, Stemple W, Abid N, Yountz M, Enayetallah A, Lampron A and Tabar V
View More Download PDF
Oral Presentation
Presented at ADPD
2024

Imaging Outcomes of a Dopaminergic Neuronal Cell Therapy for Parkinson’s Disease: 18-Month Results

Ma Y, Henchcliffe C, Sarva H, Lozano A, Fasano A, Kalia S, Yu K, Brennan C, Jennings N, Stemple W, Abid N, Yountz M, Enayetallah A, Lampron A, Tabar V, Eidelberg D
View More Download PDF
Poster
Presented at ADPD
2024

Non-motor Effects of Bemdaneprocel for Parkinson’s Disease: Results up to 18 Months From a Phase 1 Study

Henchcliffe C; Sarva H; Lozano A; Fasano A; Kalia S; Yu K; Brennan C; York M; Stemple W; Abid N; Yountz M; Enayetallah A; Lampron A; Tabar V
View More Download PDF
Poster
Presented at MDS
2023

Dopaminergic Neuronal Cell Therapy for Parkinson’s Disease: Results From a Phase 1 Study of Bemdaneprocel

Henchcliffe C, Sarva H, Lozano A, Fasano A, Kalia S, Yu K, Brennan C, Stemple W, Abid N, Yountz M, Enayetallah A, Lampron A and Tabar V
View More Download PDF
Showing 1 - 10 of 10